🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Aarey Drugs & Pharmaceuticals Limited AAREYDRUGS NSE

Company Profile ↓
₹81.80
+19.45% 1Y
Mkt Cap₹231.94 Cr
P/E58.85
P/B1.55
52W High₹99.25
52W Low₹50.75
Book Value₹52.87
EPS (TTM)₹1.39

Company Overview

Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) is a publicly traded company listed on NSE with a market capitalization of ₹231.94 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.33.

Recent Developments

  • Mar 2026 Revenue of ₹472.27 Cr (-0.4% YoY); net profit ₹3.97 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -0.4%, earnings -1.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 4.6%, profit CAGR 1.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.58%
1 Year:-0.35%

Compounded Profit Growth

5 Years:1.71%
1 Year:-1.40%

Stock Price Performance

1 Year:+19.45%
6 Months:+27.79%
3 Months:-11.20%
1 Month:-7.03%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 64% of range
₹50.75 ₹99.25
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)52.63 · Neutral
Price Performance
1M-7.03%
3M-11.20%
6M+27.79%
1Y+19.45%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 58.9.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
58.85
Industry PE
-
Forward P/E est.
59.69
PEG Ratio
-
Book Value
₹52.87
Price to Book
1.55
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
4.58%
Profit 5Y
1.71%
Revenue (YoY)
-0.35%
Earnings (YoY)
-1.40%

Profitability & Returns

ROCE
6.84%
ROE
2.64%
ROA
1.33%
Profit Margin
0.84%
Op Margin
0.91%
Gross Margin
3.76%
EPS (Latest Qtr)
₹0.55
EPS (TTM)
₹1.39

Balance Sheet & Liquidity

Debt/Equity
0.33
Quick Ratio
1.53
Current Ratio
1.81
Debt
₹49.96 Cr
Total Assets
₹297.25 Cr
Current Assets
₹262.94 Cr
Working Capital
₹117.87 Cr

Ownership

Promoter Holding
51.15%
Chg in Prom Hold
-
FII / Inst Holding
1.05%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹231.94 Cr
Total Revenue (TTM)
₹472.27 Cr
EBITDA
₹13.27 Cr
Free Cash Flow
₹-2.27 Cr
Operating Cash Flow
₹10.14 Cr
Shares Outstanding
₹2.84 Cr
Gross Margin
3.76%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -108.10 Cr102.21 Cr84.16 Cr96.43 Cr189.47 Cr
Cost of Revenue -109.18 Cr97.84 Cr80.48 Cr96.80 Cr179.39 Cr
Gross Profit --1.08 Cr4.37 Cr3.68 Cr-36.99 L10.08 Cr
Operating Expenses -3.54 Cr3.16 Cr1.73 Cr1.97 Cr6.59 Cr
Operating Income --4.61 Cr1.22 Cr1.95 Cr-2.34 Cr3.49 Cr
EBITDA -3.33 Cr3.25 Cr3.44 Cr2.67 Cr3.91 Cr
Interest Expense -1.30 Cr1.04 Cr1.26 Cr91.91 L1.78 Cr
Pretax Income -1.62 Cr1.73 Cr1.48 Cr92.37 L1.28 Cr
Tax Provision -1.15 Cr35.69 L45.82 L35.42 L-27.73 L
Net Income -47.01 L1.37 Cr1.02 Cr56.95 L1.56 Cr
Diluted EPS -0.170.480.360.200.55

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -412.85 Cr395.10 Cr473.94 Cr472.27 Cr
Cost of Revenue -403.84 Cr381.90 Cr462.06 Cr454.51 Cr
Gross Profit -9.01 Cr13.20 Cr11.88 Cr17.76 Cr
Operating Expenses -7.00 Cr10.38 Cr10.93 Cr13.44 Cr
Operating Income -2.00 Cr2.82 Cr95.39 L4.32 Cr
EBITDA -10.19 Cr11.35 Cr12.71 Cr13.27 Cr
Interest Expense -2.61 Cr4.31 Cr4.66 Cr5.00 Cr
Pretax Income -6.01 Cr5.34 Cr6.10 Cr5.41 Cr
Tax Provision -2.24 Cr65.93 L2.08 Cr1.45 Cr
Net Income -3.77 Cr4.68 Cr4.02 Cr3.97 Cr
Diluted EPS -1.491.841.421.39

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -291.32 Cr303.29 Cr290.59 Cr297.25 Cr
Current Assets -270.61 Cr282.59 Cr265.62 Cr262.94 Cr
Cash & Equivalents -70.58 L1.59 Cr1.47 Cr1.40 Cr
Inventory -28.82 Cr34.68 Cr45.49 Cr41.54 Cr
Receivables -189.78 Cr184.48 Cr133.46 Cr129.65 Cr
Total Liabilities -173.92 Cr170.54 Cr152.11 Cr146.82 Cr
Current Liabilities -168.14 Cr166.55 Cr149.21 Cr145.08 Cr
Long Term Debt -4.36 Cr3.22 Cr1.99 Cr97.40 L
Total Debt -37.72 Cr31.35 Cr34.86 Cr49.96 Cr
Total Equity -117.41 Cr132.76 Cr138.48 Cr150.42 Cr
Shares Outstanding -2.54 Cr2.81 Cr2.85 Cr2.84 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow --1.28 Cr-2.99 Cr10.30 Cr10.14 Cr
Investing Cash Flow -44.10 L-1.70 Cr-5.94 Cr-12.41 Cr
Financing Cash Flow -1.35 Cr5.58 Cr-4.48 Cr2.20 Cr
Capital Expenditure --1.04 Cr-72.23 L-5.20 Cr-12.41 Cr
Free Cash Flow --2.33 Cr-3.72 Cr5.10 Cr-2.27 Cr
Net Change in Cash -51.39 L88.87 L-12.11 L-7.47 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -2.2%3.3%2.5%3.8%
Operating Margin % -0.5%0.7%0.2%0.9%
Net Margin % -0.9%1.2%0.8%0.8%
ROE % -3.2%3.5%2.9%2.6%
ROCE % -1.6%2.1%0.7%2.8%

Shareholding Pattern

Insiders
51.15%
Institutions
1.05%
Public Float
2.16%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AAREYDRUGS

Google News Mon, 20 Apr 2026

AMBALALSA Stock Price and Chart — NSE:AMBALALSA - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1XMmpqWktLeGR1d0ZFc0RodlFjNkFIeUdOTm5CZGxqSGVGSlZtUUtIM2U3Nlh1MTUtRWp2QURpT2JpeXFsQm10TEp2bExZNmx3c3VGNjQ3b2VNSUpqSEpZ?oc=5" target="_blank">AMBALALSA Stock Price and Chart — NSE:A…

Google News ue, 02 Jun 2026

Aarey Drugs FY26 net profit rises, revenue falls marginally - scanx.trade

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNTXR1MU5pU2RVYmVYdWlhTEtmenlfcnA3dGtVSjFNcEt3aEFMdG9xcjdvZF9rNkx0Z1pJWjBhVzJNSUJWQlBTaDZHODcwWlE4RDN0bzdTeVdFYW9GaG1TQU1wSFE1REIyN0MtbjlHak1MSlRYcHJ2M3A1VndkaEJFbnhJWGFTcDQwR0tzZ2…

Google News Fri, 06 Aug 2021

AAREYDRUGS Stock Price and Chart — NSE:AAREYDRUGS - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5NYm5rMjMxdHRZYzJLcnQ3b1gwSVdndzVfMVBwVEFoQjFDRkZwc1FuaFlyaGlwZnE1R2ZLODVJN0ZWNE1QNTJuSzctVDJJR0pZUWtrbVJhOVBCOTdRRHBqUA?oc=5" target="_blank">AAREYDRUGS Stock Price and Chart — NS…

Google News hu, 29 May 2025

Aarey Drugs & Pharmaceuticals Ltd. Share Price Live Today - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxPbC16aFNiMmtFcXdsd2xseWtyZ3FDVmkxaWxGb1lXV2l5S0dWc0VCN2RXR3ltOG1OQ0VSaTRDWXhFdGoyVTlmbUt2RmZEVE15ZXZkUTZmdTJXWHRpcEwtU0FkYUhSUUxsRG5BXy1qMTJhUVp5THl0a1d0UmZELXlnZkNLd280RFBXQVBQZ1…

Google News Mon, 21 Nov 2022

Aarey Drugs & Pharmaceuticals Ltd. Share Price Today | Aarey Drugs Live NSE/BSE - Value Research

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOcWdIdEZ0eFdGUnAzTlpfaFZxNU9oSWRfZjViWFprTHI4QnRPT1pKYVFvalB5TlFKZjZxRWRDVTI1YXNmRUxkd25tTW0ydnJUeUZHclR2akF5dmxWblVyRnlqeUYzZzJCRTEzTEdqMldTSXVvNjZVUUxyUC1ZZ1pBZnU3TWRRbHhf?oc=5"…

Google News hu, 13 Oct 2022

Indo Amines Ltd leads gainers in 'B' group - business-standard.com

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNV19NbG9peW5qQVBqblJTdld5TUJsOGNIVUYtR2RhekxLenNYQUo5UWs2em5iSjVCN01PdEdWbzl0UVlFN3V2aFpsVDJ0WXpGZFVCeTVsQWNMTHFZQmZTTDBZU29WRk9rZ1VGUWkweXIxVkg1QVJZeXE5MmZVQ0tGbWo3QkNvMnllZHBfaj…

AAREYDRUGS — Frequently Asked Questions

What is the current share price of Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)?

As of 2026-08-07 06:31 IST, Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) trades at ₹81.80 on NSE. Its 52-week range is ₹50.75 to ₹99.25.

What is the market capitalisation of AAREYDRUGS?

Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) has a market capitalisation of ₹231.94 Cr on NSE.

What is the P/E ratio of AAREYDRUGS?

AAREYDRUGS trades at a trailing price-to-earnings (P/E) ratio of 58.85. Its price-to-book (P/B) ratio is 1.55.

What is the return on equity (ROE) of AAREYDRUGS?

AAREYDRUGS has a return on equity (ROE) of 2.64%. Its return on capital employed (ROCE) is 6.84%.

Is AAREYDRUGS a good stock to buy?

This page provides a data-driven analysis of Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space